Obesity-Related Indices and Albuminuria in Type 2 Diabetes

November 2, 2026 updated by: Mahmoud Marouf Sadek, Assiut University

Obesity-Related Indices in Association With Albuminuria Level in Patients With Type 2 Diabetes Mellitus

This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Type 2 diabetes mellitus is a leading cause of chronic kidney disease. Obesity-related indices such as body mass index, waist-to-height ratio, body roundness index, visceral adiposity index, and triglyceride-glucose index are simple measures of body composition and metabolic status.

This observational study will calculate multiple obesity-related indices and measure urine albumin-to-creatinine ratio in adult patients with type 2 diabetes mellitus.

Study Type

Observational

Enrollment (Estimated)

349

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients aged 18 years or older with established type 2 diabetes mellitus attending Assiut University Hospitals.

Description

Inclusion Criteria:

  • - Age 18 years or older
  • Established diagnosis of type 2 diabetes mellitus
  • Ability to provide written informed consent

Exclusion Criteria:

  • - Type 1 diabetes mellitus
  • Pregnancy
  • Acute kidney injury
  • Known primary glomerular disease
  • Active urinary tract infection
  • Decompensated liver disease or active malignancy
  • Advanced chronic kidney disease (eGFR <60 mL/min/1.73m²)
  • Conditions preventing reliable anthropometric assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_ONLY
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Patients with Type 2 Diabetes Mellitus

Adult patients with established type 2 diabetes mellitus who will undergo anthropometric measurements and laboratory assessment of albuminuria.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine albumin-to-creatinine ratio
Time Frame: Baseline

Mean urine albumin-to-creatinine ratio in milligrams per gram.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Estimated glomerular filtration rate
Time Frame: Baseline

Mean estimated glomerular filtration rate calculated by the CKD-EPI 2021 equation in milliliters per minute per 1.73 square meters.
Baseline
Body mass index
Time Frame: Baseline

Mean body mass index calculated as weight in kilograms divided by height in meters squared.
Baseline
Waist-to-height ratio
Time Frame: Baseline

Mean waist-to-height ratio calculated as waist circumference divided by height.
Baseline
Body roundness index
Time Frame: Baseline

Mean body roundness index calculated from waist circumference and height.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Chair: Manal E EzzEl-dine Abdel-Mooty, prof, Internal Medicine Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 10, 2026

Primary Completion (Estimated)

November 10, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 2, 2026

First Posted (Actual)

November 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Obesity-Indices-T2DM-Assiut

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe